Skip to main content

01-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | Article

Researcher comment: Apalutamide addition improves metastatic CSPC survival

Conference coverage direct to your inbox

Study author Axel Merseburger takes us through the TITAN trial investigating the addition of apalutamide to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting, and also addresses the key question of how physicians should choose between the available treatment options (3:03).

Back to the conference hub​​​​​​​

Related topics

More on this topic

Image Credits